Clinical cross-reactivity between danaparoid and heparin antibodies successfully managed with bivalirudin.
Shapiro
Maurice
M
Department of General Intensive Care, Rabin Medical Center, Beilinson Campus, Petah Tikvah and Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel. moriss@clalit.org.il
Cohen
Johnathan
J
Inbal
Aida
A
Singer
Pierre
P
D000925:Anticoagulants / Q000276:immunology* / Q000494:pharmacology; D000991:Antithrombins / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000276:immunology* / Q000494:pharmacology; D003429:Cross Reactions / Q000187:drug effects / Q000276:immunology; D003871:Dermatan Sulfate / Q000276:immunology* / Q000494:pharmacology; D006496:Heparinoids / Q000009:adverse effects / Q000276:immunology; D006497:Heparan Sulfate / Q000276:immunology* / Q000494:pharmacology; D006629:Hirudins; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced
D000925:Anticoagulants; D000991:Antithrombins; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006496:Heparinoids; D006497:Heparan Sulfate; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; C035838:danaparoid; C074619:bivalirudin